Mandala Bioworks Private Limited (MBPL) was incorporated on 18th August 2020.

The MBPL team came together to play a part in the exciting and growing worldwide effort to make biosciences and biotechnology more consumer accessible and consumer friendly.

In our first year of existence we have successfully developed breakthrough technologies towards the same via the Govt. of India's BIG grant, and validated our technology at lab and pilot scale.

We believe human diagnostics in particular will be substantially less invasive while being cheaper and faster in the near future. They may even be increasingly possible to do at home, on a more periodic if not daily basis.

COVID-19 has made palpable the consumer demand for these products and services and created a wave of interest that is drawing the best minds, scientists, engineers and investors who will be engaged in solving these problems and bringing them to market. MBPL seeks to be a dominant market leader in the coming Consumer Biotechnology revolution

The Holy Grail of Consumer Biotech

In order to be consumer friendly, whether in the lab or at home, this paradigm shift requires that conventional tests are reimagined and redesigned to work with the smallest and least invasive sample possible - fingerprick blood, if not ideally saliva etc.

So far only a few such tests have reached commercial viability. Primarily this is on account of the fact that, while a small sample of saliva or fingerprick blood can be easily extracted, the subsequent testing is much more complicated.

Why is this so hard?

The compounds that are being detected in a few mircoliters of saliva or blood are often many magnitudes below the detection capabilities of current systems. Our current tests have been designed to expect much larger volumes in order to make these reactions work and interface with the sensors that we have been using successfully for decades to detect and quantify these often invisible reactions.

When you change the scale, the rules change too. We need to redesign core systems to make these tests work

The Mandala Advantage

MBPL has developed a detection system that breaks through this barrier using bioluminescence - the light emitting chemistry of nature - most popularly depicted in fireflies.

Our system can work at volumes that make saliva/fingerprick testing etc viable, detect extremely faint light signals many magnitudes below the state of the art flourescence based detection systems on the market. And it can be easily adapted for multiple targets, so that a range of tests and methods that were restricted to research settings may now be commercialised on top of these technologies.

Our bioluminescent probe system is also cost effective.

The base cost per test is less than two US dollars.

The base cost of the detection system is less than four hundred US dollars.